Does Wegovy Work Better Than Mounjaro for Some People? A Personalized Look at Weight Loss Solutions

Last reviewed: June 20, 2026

Last updated: June 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Both semaglutide (Wegovy) and tirzepatide (Mounjaro) show strong clinical evidence for weight loss, with tirzepatide demonstrating average reductions of 20-22% of body weight in trials compared to semaglutide's 15-17%. Yet some patients lose twice as much weight on one drug versus the other—not because of willpower or diet, but because of how their genetic makeup interacts with each medication's mechanism of action. Understanding these differences helps you make an informed choice about your personalized weight loss journey.

How Semaglutide and Tirzepatide Work Differently in Your Body

Semaglutide activates one hormone receptor called GLP-1R, which signals fullness in your brain and slows stomach emptying. This single-pathway approach works reliably for many people, which is why it became the first mainstream GLP-1 therapy. Tirzepatide, by contrast, activates both GLP-1R and a second receptor called GIPR, creating a dual-hormone effect that mimics two natural appetite-suppressing hormones your body produces naturally.

The dual activation in tirzepatide appears to amplify hunger suppression and increase metabolic activity in some individuals. However, this doesn't mean tirzepatide is universally superior—it means your genetic variation at these receptor sites determines how much benefit you'll receive from activation. Some people have genetic variants that make their GLP-1R extremely sensitive, while others have stronger GIPR responsiveness. PlexusDx tests for key variants including GLP1R rs6923761 and GIPR rs1800437 to map your peptide pathway strength.

Genetic Variants That Predict Your Medication Response

Your FTO gene (fat mass and obesity-associated) contains a variant, rs9939609, that influences how your body stores and burns fat. People carrying certain FTO variants show greater hunger-driven eating behavior and may respond more dramatically to dual-pathway activation. Similarly, MC4R rs17782313 affects melanocortin signaling, a master switch for appetite regulation. When this variant is present, both semaglutide and tirzepatide can be effective, but the magnitude of response often depends on which receptor your unique genetic profile favors.

PlexusDx Precision Peptide Genetic Testing maps 14 biological pathways and 49 peptides across 150+ genetic insights to reveal your personalized medication profile. This isn't pharmacogenomic testing (drug metabolism), but peptide-pathway genetic testing—it shows which weight loss mechanisms your body is primed to respond to. A patient with high GLP-1R sensitivity but lower GIPR activation capacity might achieve better results with semaglutide alone, while someone with robust dual-receptor function could see superior outcomes with tirzepatide.

Clinical Evidence: Head-to-Head Comparison and Real-World Outcomes

The SURMOUNT trials showed tirzepatide participants lost 20-22% of baseline body weight over 68 weeks, while the SUSTAIN trials demonstrated semaglutide's 15-17% average loss over similar periods. However, individual variation within both groups was substantial—some semaglutide users lost over 20%, while some tirzepatide users plateaued at 12-15%. This variance isn't random; it correlates with genetic factors affecting peptide receptor density and sensitivity. Compounded tirzepatide injection from licensed 503A pharmacies preserves the same clinical mechanism as brand Mounjaro, starting at $249/month with consistent pricing regardless of dose escalation.

Side effect profiles also diverge by genetics. Gastrointestinal symptoms occur in 20-40% of GLP-1 users but vary in intensity based on how quickly your gut receptors adapt. Tirzepatide's dual activation sometimes triggers stronger initial nausea, while semaglutide users often experience milder GI adjustment. Genetic variants affecting serotonin and dopamine processing influence how you perceive these sensations. Understanding your genetic predispositions helps you anticipate tolerability and make proactive adjustments with your provider.

Choosing Between Semaglutide and Tirzepatide: A Personalized Framework

If you have strong genetic markers favoring GLP-1R function, single-agent semaglutide might deliver excellent results with fewer side effects. PlexusDx offers compounded semaglutide injection starting at $149/month, with pricing that stays flat as your dose increases. Conversely, if your genetic profile shows robust capacity for dual-pathway activation (high GLP1R and GIPR sensitivity), tirzepatide injection begins at $249/month and may produce superior weight loss through enhanced hormone signaling. Some patients respond optimally to oral formulations; PlexusDx offers compounded oral semaglutide at $249/month and oral tirzepatide at $279/month.

PlexusDx Precision Peptide Genetic Test ($99 add-on after your first treatment month) provides clarity on your individual peptide-pathway profile, removing guesswork from medication selection. You can start with your provider's recommended first-line therapy while the genetic results are processed, then adjust if needed based on response and your genetic insights. All PlexusDx medications ship to all 50 states without insurance requirements, and they're HSA/FSA eligible. Your dose may need to go up; your price won't—a commitment to making precision weight loss accessible.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Why does my friend lose weight faster on Mounjaro than I do on Wegovy?

Your genetic variants at GLP1R, GIPR, and metabolic pathways determine how strongly you respond to each medication's mechanism. Your friend may have genetic variants that favor dual-pathway activation, while your genetics may be optimized for single GLP-1R signaling. PlexusDx Precision Peptide Genetic Testing reveals your unique peptide-pathway profile to explain these differences.

Is tirzepatide clinically proven to work better than semaglutide?

Tirzepatide showed higher average weight loss (20-22%) than semaglutide (15-17%) in head-to-head trials, but individual outcomes vary widely based on genetics. Both medications are evidence-based and effective; the best choice depends on your personal peptide-pathway genetics and tolerability profile.

How much does PlexusDx tirzepatide injection cost compared to brand Mounjaro?

PlexusDx compounded tirzepatide injection starts at $249/month from licensed 503A pharmacies—typically a fraction of brand Mounjaro's retail cost. Pricing remains flat regardless of dose escalation, and it's available in all 50 states without insurance or membership fees. HSA and FSA accounts are accepted.

Can I switch from semaglutide to tirzepatide if I'm not seeing results?

Yes, medication switches are common and safe when guided by your provider. Many patients try one GLP-1 for 8-12 weeks before evaluating response; if results plateau or side effects are problematic, switching to a different mechanism may help. PlexusDx genetic testing can inform whether a switch aligns with your peptide-pathway profile.

What does the PlexusDx Precision Peptide Genetic Test actually measure?

It tests peptide-pathway genetic variants (not drug metabolism), including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313, mapping 14 pathways and 49 peptides to reveal 150+ personalized insights. This tells you which weight loss mechanisms your genetics favor, guiding semaglutide versus tirzepatide and other precision therapy choices.

Related Reading

• Why Do Some People Cope With Stress Better Than Others
• Wegovy For Weight Loss 2
• Mounjaro For Weight Loss 2
• Wegovy Weight Loss Pills

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.